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Abstract 
Background: Gender differences in asthma perception and control have been reported. The PROXIMA observational 
study assessed these outcomes in a cohort of Italian severe allergic asthma (SAA) patients. This post hoc analysis of 
the PROXIMA results was aimed at assessing gender differences in SAA in a real-world setting, focusing on disease 
perception and impact on quality of life (QoL).
Methods: The PROXIMA study was an observational, multicenter study, consisting of a cross-sectional and a 
prospective longitudinal phase, including adult outpatients diagnosed with SAA at step 4 requiring a therapeutic 
step-up. Patients on omalizumab treatment at baseline were included in the 12-month longitudinal phase. Disease 
control was assessed by the Asthma Control Questionnaire (ACQ) score, patients’ disease perception by the Brief Illness 
Perception Questionnaire (BIPQ), and QoL by the EuroQoL five-dimensional three-level questionnaire (EQ-5D-3 L) at 
baseline and after 6 and 12 months. Two regression models were used to evaluate the association between gender and 
BIPQ total score and EQ-5D-3L score, respectively.
Results: 357 patients (65% females) were analyzed for the cross-sectional phase and 99 (62.6% females) for the 
longitudinal phase. The prevalence of perennial and seasonal aeroallergens was similar between genders. ACQ 
score decreased similarly during omalizumab treatment at 6 and 12 months in both genders; no gender differences 
were observed in control rates. Asthma perception was worse among females at all study visits reaching statistical 
significance at 12 months (mean (SD) B-IPQ total score 41.8 (9.4) vs 35.6 (12.0); T test p-value (males vs females) < 0.05). 
Statistically significant gender differences were observed for some specific items, with males reporting less symptom 
experience, concern about the disease, and emotional impact at 12-months. The results of the multivariate regression 
model for repeated measures showed that overall treatment with omalizumab improved disease perception overtime 
regardless from gender. Males reported a significantly better QoL compared to females at both 6 and 12 months.
Conclusions: In this real-world setting, females confirmed to have a worse perception of asthma, feel it as more 
symptomatic and suffer a greater impact on their QoL, even though having similar baseline severity and obtaining 
similar level of control.
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Background
Asthma is a chronic disease that affects more than 
300 million people of all ages and ethnic groups 
worldwide and represents a major health care burden 
[1]. Furthermore, its prevalence is increasing together 
with that of allergic diseases: in Italy, in particular, the 
asthma epidemic does not seem to slow down, with an 
increase in prevalence of 38% reported between 1990 
and 2010, in parallel with a similar increase in asthma-
like symptoms and allergic rhinitis [2]. Severe asthma 
affects 5–10% of all asthma patients [3], often remaining 
uncontrolled despite high-dose inhaled corticosteroids 
(ICS) and long-acting  beta2-agonists (LABA). Among 
adults, the incidence and severity of asthma are higher 
in females than in males, particularly between the 4th 
and 6th decade [4, 5]; over the age of 35, asthma was 
reported to be 20% more frequent in females than in 
males [6]. On the other hand, before puberty boys are 
more frequently affected than girls [4, 7] and in the 
elderly the differences in prevalence tend to decrease [8]. 
Although the basis for these gender differences are not 
yet fully understood, several hypotheses have been made. 
The above reported trends in asthma prevalence suggest 
that sex hormones are implicated in asthma pathogenesis, 
with female sex hormones and their receptors favoring 
asthma development and male sex hormones and their 
receptors exerting a protective effect. Some authors have 
suggested a greater hyper-responsiveness in females than 
in males [9], others have underlined differences between 
genders in lung capacity [10, 11]. Differences have also 
been reported in perception of air flow obstruction, with 
females complaining significantly lower general health 
status, more symptoms and more activity limitations [12, 
13], and in health-related quality of life (QoL) [14, 15].
The PROXIMA (Patient Reported Outcomes and 
 Xolair® In the Management of Asthma) study was 
an observational, non-controlled, multicenter, two-
phase study in Italian severe allergic asthma (SAA) 
patients, aimed at assessing the prevalence of perennial 
environmental allergies (during the cross-sectional phase) 
and the rate of disease control after up to 12  months of 
omalizumab treatment (during the longitudinal phase). 
The secondary objectives of the study included the 
assessment of patients’ disease perception and level 
of asthma control during both the cross-sectional and 
longitudinal phases and patients’ compliance to and 
persistence with omalizumab, rate of exacerbations and 
patients’ QoL during the longitudinal phase [16, 17].
Novartis has put in place a wide gender-medicine 
project, called MetaGeM, with the purpose to evaluate 
gender differences in clinical outcomes, therapeutic 
approaches and safety parameters, by means of post 
hoc analyses and meta-analyses of previously conducted 
observational trials. The MetaGeM project includes 11 
Italian observational studies in different clinical areas, 
including immune-mediate disorders, organ transplants, 
and infectious, central nervous system, cardiovascular 
and respiratory diseases, performed between 2002 and 
2016. Within the MetaGeM project, a post hoc analysis 
of the results of both phases of the PROXIMA study 
has been conducted with the aim of exploring gender 
differences in SAA in a real-world setting, with particular 
focus on disease perception and impact on patients’ QoL. 
We here report the results of this post hoc gender analysis 
aimed to evaluate in the PROXIMA SAA population (i) 
the association between gender and presence of perennial 
or seasonal allergies at baseline and, in patients on 
omalizumab treatment included in the longitudinal phase, 
the effect of gender on (ii) asthma control, (iii) asthma 
perception and (iv) QoL during 12 months of follow up.
Methods
The PROXIMA study was an observational, non-
controlled, multicenter cohort study, conducted from 
December 27, 2013 to June 21, 2016 at 25 Italian centers 
specialized in asthma treatment, consisting of two phases, 
a cross-sectional and a prospective longitudinal phase. 
Outpatients aged ≥ 18 years, diagnosed with SAA at step 
4 according to GINA 2012 guidelines and requiring a 
therapeutic step-up [18, 19], were included in the cross-
sectional phase. Patient unable to complete the patient 
questionnaires or included in an experimental study at 
entry were excluded.
Those who were on treatment with omalizumab at 
baseline visit were included in the 12-month longitudinal 
phase, provided that they had started omalizumab as 
per clinician judgement (according to AIFA criteria) not 
earlier than 15 days before enrolment and within 30 days 
after enrolment.
In the PROXIMA study, the level of disease control 
had been assessed by the Asthma Control Questionnaire 
(ACQ) score, a validated tool with a 7-point scale, where 0 
means well-controlled and 6 extremely poorly controlled 
asthma [20]. According to Van den Nieuwenhof L et  al. 
[21], an ACQ total score between 0 and 4 indicates a good 
to moderate symptom control and a score ≥ 4 a poor/very 
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poor symptom control. Patients with an ACQ score < 4 at 
either 6 or 12  months were so classified as “controlled” 
and patients with a score of ≥ 4 as uncontrolled.
Patient’s disease perception had been assessed by 
means of the Brief Illness Perception Questionnaire 
(B-IPQ), a validated 9-item questionnaire designed to 
rapidly assess cognitive and emotional representations 
of illness [22]. Five of the items assess cognitive illness 
representations (consequences, Item 1; timeline, Item 2; 
personal control, Item 3; treatment control, Item 4; and 
identity, Item 5), two assess emotional representations 
(concern, Item 6 and emotions, Item 8) and one assesses 
the level of illness comprehension (Item 7). Assessment of 
the causal representation (Item 9) is by an open response 
item, which asks patients to list what they consider the 
three most important causal factors in their illness. All the 
questionnaire items (except item 9) are rated using a 1-to-
10 response scale; for all items 1 means best and 10 worst 
perception of the disease with the exception of items 3, 4 
and 7 where the score is reverse (i.e. 1 means worst and 10 
best perception of the disease). B-IPQ total score ranges 
between 8 and 80, with a higher score reflecting a worse 
perception of the disease; it was calculated by summing 
the responses to items 1 to 8 (after reversing the score for 
items 3, 4 and 7).
The patients’ QoL had been measured by the EuroQoL 
five-dimensional three-level questionnaire (EQ-5D-3L), 
a validated and standardized measure of health status 
developed by EuroQol Group to provide a simple generic 
measure of health status for clinical and economic 
evaluation [23, 24]. All these evaluations had been 
performed at baseline and after 6 and 12 months. Detailed 
study design, objectives, and overall results have been 
reported elsewhere [16, 17].
Statistical methods
Being this a post hoc analysis, all patients evaluated in the 
cross-sectional and longitudinal phases of the PROXIMA 
study were considered in the gender analysis, with no 
formal a priori hypothesis about gender distribution 
of patients. For the cross-sectional phase, all patients 
fulfilling inclusion/exclusion criteria were analyzed; for 
the longitudinal phase patients treated with at least one 
dose of omalizumab at study entry (from 15 days before to 
30 days after enrolment) who completed the longitudinal 
phase on treatment with omalizumab (i.e. who did not 
discontinue omalizumab treatment during the whole 
follow-up period) and with available ACQ assessment at 
baseline and during the follow-up period were considered.
The continuous, normally distributed variables were 
expressed as a mean ± SD and comparisons between 
groups were performed with the parametric Student’s 
t test. In case of not normally distributed parameters, 
median and interquartile range (IQR) were provided and 
males were compared to females by means of the non-
parametric Wilcoxon rank sum test. Absolute and relative 
frequencies were calculated for qualitative data and 
differences between categorical variables were tested by 
Chi square or Fisher exact test. The significance threshold 
was set as 0.05 (all p-values presented are exploratory, 
so no correction for multiple testing was applied [25]). 
Missing values were not replaced and did not contribute 
to the analysis of the variable.
Eight bivariate logistic regression models were used 
to assess the association between perennial asthma 
and gender, keeping constant the effect of the following 
clinically relevant covariates: age, duration of asthma, age 
at diagnosis and serum IgE level (included in the model 
as continuous variable), presence of comorbidities (yes; 
no), number of exacerbations during the last year (0; ≥ 1), 
smoking (current/former smoker; no smoker), and ACQ 
score (< 4; ≥ 4).
Two regression models for repeated measures—since 
outcomes were assessed at baseline and follow-up visits—
were used to evaluate the effect of gender on (1st model) 
patients’ disease perception (B-IPQ total score) and (2nd 
model) QoL (EuroQoL score), keeping constant the effect 
of other clinically relevant covariates. As covariates the 
following were included: age and duration of asthma (as 
continuous variable), presence of comorbidities at baseline 
visit (yes; no), smoking at baseline (current/former 
smoker; no smoker), number of exacerbations in the year 
before baseline (0; ≥ 1), total omalizumab dose taken 
during follow-up (as continuous variable), concomitant 
medications with ICS, ICS + LABA, oral corticosteroids 
(OCS) (yes; no). We were also interested in estimating 
the effect of time on patients’ disease perception and 
QoL, holding gender and all the other variables included 
in the model constant. For this reason, the visit (baseline, 
6-month follow up, 12-month follow-up) was also 
included as covariate in the two models.
Statistical analysis was performed using SAS v9.4 and 
Enterprise Guide v7.1. Project management including 
data banking, quality control and statistical analysis, 
was performed by Medineos Observational Research 
(Modena, Italy).
Results
The analyzed population included 357 patients in the 
cross-sectional phase—232 (65.0%) females—and 99 
patients in the longitudinal phase—62 (62.6%) females. 
Median (IQR) age at study inclusion was 52.3 (40.2–61.9) 
years in females and 50.2 (38.1–64.5) years in males. 
Demographic and baseline clinical characteristics by 
gender and study phase are summarized in Table 1. The 
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only significant difference was registered in FEV1, which 
was lower in females than in males. The prevalence 
of perennial and seasonal aeroallergens in the cross-
sectional population was 87.4% vs 12.6% respectively 
in females and 92.6% vs 7.4% respectively in males (Chi 
square test, p = 0.1415), showing no association between 
gender and presence of perennial or seasonal allergy. 
Bivariate logistic regression models showed no relevant 
association between perennial asthma and gender too 
(Table  2); the association between gender and perennial 
asthma keeping constant the presence of exacerbations 
during the year before baseline (OR of perennial asthma 
females vs males 0.362, 95% CI 0.143–0.918), in fact, 
could be influenced by data distribution. 
In the original PROXIMA study the mean (SD) 
compliance rate to omalizumab (assessed in terms of 
proportion of administered over the total number of 
planned injections) was 96.9 (7.8)% during the 12-month 
follow-up. In the longitudinal phase, the mean (SD) 
total dose of omalizumab—whose posology depends on 
serum IgE level and body weight—injected during the 
follow-up period was 6309.3 (3820.1) mg in females and 
6934.5 (4148.4) mg in males. Asthma medications taken 
concomitantly to omalizumab are summarized in Table 3. 
Females were taking overall more OCS in different 
combinations (18.5% in females vs 8.8% in males) and less 
inhaled therapies—ICS alone or plus ICS/LABA fixed 
combination without OCS—than males (79.6% in females 
vs 91.2% in males). However, no statistically significant 
differences by gender emerged.
Median ACQ score, expressing the level of asthma 
control (the lower the score, the greater the control), 
decreased from baseline both at 6 and 12 months in males 
and females (Table  4). Considering the score of 4 as the 
cut-off for controlled asthma [20], as shown in Fig. 1, no 
gender differences were observed in the control rates, 
both at baseline and during follow-up (Chi square/Fisher 
test % of controlled patients vs gender p-value > 0.05; 
test not performed at 6 months because all patients had 
controlled asthma).
The B-IPQ scores at all time points by gender for all 
items and total score are reported in Table  5. Asthma 
perception was slightly worse among females than 
males at all study visits reaching statistical significance 
at 12-month follow-up visit (mean (SD) B-IPQ total 
score 41.8 (9.4) in females vs 35.6 (12.0) in males; T-test 
p-value (males vs females) < 0.05). Statistically significant 
gender differences were observed for some specific 
items, with males reporting less symptom experience 
(item 5), less concern about the disease (item 6), and 
less emotional impact (item 8) than females at 12-month 
follow-up. Moreover, males felt to better understand 
Table 2 Association between  gender and  perennial asthma: bivariate logistic regression models adjusted for  relevant 
covariates
The model estimates the odds ratio of having perennial asthma
95% Wald Confidence Limits are showed
OR gender
(Females vs males)
[95% CI]
OR other covariates*
[95% CI]
*Age at baseline (years) n = 335 0.556 [0.252–1.227] 0.988 [0.965–1.011]
*Presence of comorbidity at baseline (no vs yes) n = 335 0.550 [0.249–1.213] 0.705 [0.352–1.414]
*Asthma duration at baseline (years) n = 325 0.541 [0.244–1.199] 0.986 [0.965–1.009]
*Age at diagnosis (years) n = 325 0.558 [0.253–1.232] 1.001 [0.981–1.021]
*N° exacerbations (0 vs ≥ 1) n = 308 0.362 [0.143–0.918] 0.470 [0.176–1.258]
*IgE serum level at baseline (IU/mL) n = 238 0.301 [0.085–1.063] 1.002 [1.000–1.003]
*Smoke (Current/former vs no smoker) n = 335 0.564 [0.256–1.244] 1.425 [0.599–3.394]
*ACQ score (< 4 vs ≥ 4) n = 318 0.534 [0.233–1.227] 0.845 [0.243–2.947]
Table 3 Ongoing asthma therapies concomitant 
to omalizumab during the observational period by gender
Only therapies that were ongoing at baseline and at 6 and 12 months were 
considered.ICS: inhaled corticosteroids; ICS/LABA: fixed combination of ICS and 
LABA; LABA: long acting  beta2-agonists; OCS: oral corticosteroids
*P-value of Fisher exact test treatment regimen (no ongoing therapies, ICS, OCS) 
vs gender (females, males) is showed
Treatment regimen Females
(N = 54)
n (%)
Males
(N = 34)
n (%)
p-value*
No ongoing therapies 1 (1.9) 0 (0.0) 0.281
ICS 43 (79.6) 31 (91.2)
 ICS only 3 (5.6) 3 (8.8)
 ICS/LABA only 33 (61.1) 21 (61.8)
 ICS + ICS/LABA 7 (13.0) 7 (20.6)
OCS 10 (18.5) 3 (8.8)
 ICS/LABA + OCS 5 (9.3) 1 (2.9)
 ICS + ICS/LABA + OCS 3 (5.6) 0 (0.0)
 ICS + OCS 2 (3.7) 2 (5.9)
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their illness at baseline (item 7) (see Table  5). The 
results of the multivariate regression model for repeated 
measures showed that overall treatment with omalizumab 
improved disease perception overtime regardless from 
gender. In fact, no effect of gender on B-IPQ total score 
exists (beta estimate females vs males: 2.83, p-value 
beta estimate > 0.05) and the B-IPQ total score was 
approximately 10 points lower at 6 and 12  months of 
follow-up compared to baseline (beta estimate 6-month 
follow up visit vs baseline visit and beta estimate 
12-month follow up visit vs baseline visit: − 10.97, p-value 
beta estimate < 0.0001).
Gender differences were observed in EuroQoL score 
at study visits, with males reporting a better QoL that 
reached statistical significance in comparison to females 
at 6 and 12  months (Fig.  2). This was confirmed by the 
results of the model for repeated measures (Table  6), 
showing that gender and time significantly impact on the 
EuroQoL score; in fact, females had a score 0.055 lower 
than males and the score improves 0.1 point from baseline 
to 12-month follow up, irrespectively of gender.
Discussion
This post hoc analysis of the PROXIMA study evaluated 
gender differences in severe asthma patients in a real-
world setting, assessing control rates following add-on 
therapy with omalizumab and focusing on disease 
perception and asthma impact on QoL. The PROXIMA 
study found that among SAA patients, perennial 
allergies were highly prevalent (95.8% based on clinical 
judgment; 83.8% based on confirmatory allergy test). 
In our by-gender analysis, no significant difference 
was found in the prevalence of perennial vs seasonal 
allergies between males and females. Our results show 
that in the PROXIMA patient population, defined by 
the requirement of step-up therapy at enrolment, males 
and females obtained similar level and rates of asthma 
control with add-on omalizumab, as measured by the 
ACQ. However, the overall perception of the disease, 
assessed by the B-IPQ, though improving on omalizumab 
treatment, was significantly worse in females compared 
to males at 12-month follow-up visit. In particular, 
some aspects of the disease were perceived significantly 
worse in females, i.e. symptom experience, concern 
about asthma, and emotional impact. We were not 
able to find in the literature whether these differences 
in the B-IPQ score translates into a clinically relevant 
difference and this can be considered a limitation of the 
Table 4 Asthma Control Questionnaire (ACQ) score 
by gender, at baseline and after 6 and 12 months
N Median (IQR)
Baseline
 Female 60 3.0 (2.1–3.6)
 Male 36 2.9 (1.9–3.7)
6 months
 Female 60 1.3 (0.6–2.4)
 Male 32 1.1 (0.6–1.5)
12 months
 Female 61 1.4 (1.0–2.4)
 Male 33 1.1 (0.4–1.7)
Fig. 1 Patients with controlled (ACQ < 4) and uncontrolled (ACQ ≥ 4) asthma by gender. Chi square/Fisher test (% of controlled patients vs gender) 
p-value > 0.05. The test was not performed at 6 months because all patients had controlled asthma
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B-IPQ score. However, our results are consistent with 
previous observations in patient populations of different 
countries, reporting that females tend to complain more 
bothersome day- and night-time asthma symptoms than 
males and have a worse perception of such symptoms 
and of disease control, despite having similar pulmonary 
function and asthma medications [15, 26, 27]. Lee and 
colleagues observed that females were more likely to 
report nocturnal awakenings and missed activities, also 
when having better pulmonary function than males [28]. 
It is not uncommon, especially in asthma, that clinical 
improvement may not correlate with patient’s experience 
[29] and this may explain the different disease perception 
observed in males and females having obtained similar 
levels of disease control. Males reported the feeling 
of a better understanding of their asthma from study 
beginning, showing to be more aware of their condition. 
Consistently with the perception results, in our study 
gender showed to exert a significant effect on patients’ 
QoL, measured by EQ-5D-3 L. While QoL improved in 
both gender after 6 and 12 months of omalizumab add-on 
compared to baseline, significant gender differences 
emerged at both follow-up visits, with females reporting a 
lower QoL than males. According to the review by Coretti 
et  al. [30], the minimal clinically important difference 
(MCID) for the EQ-5D index ranges from 0.03 to 0.54; 
therefore, the difference registered in our study between 
males and females can be considered somewhat clinically 
relevant. Thus, also in terms of asthma impact on QoL, 
females showed to be more heavily affected by the disease. 
Table 5 Mean B-IPQ scores by gender at baseline and at 6 and 12 months
Mean (SD) were showed
B-IPQ items range between 1 and 10; for all items 1 means best and 10 worst perception of the disease with the exception of items 3, 4 and 7 where score is reversed 
(and so 1 means worst and 10 best perception of the disease)
B-IPQ total score ranges between 8 and 80, with a higher score reflecting a worse perception of the disease
*Student’s t test p-values were showed. Statistically significant p-values are in italic
Items Baseline 6 months 12 months
n p-value* n p-value* n p-value*
1. Consequences: How much does your illness affect your life?
Females 61 7.3 (1.9) 0.830 61 5.0 (2.4) 0.304 62 5.1 (2.6) 0.292
Males 37 7.2 (1.9) 35 5.6 (2.9) 36 4.6 (2.8)
2. Timeline: How long do you think your illness will continue?
Females 60 8.3 (2.2) 0.229 59 7.4 (2.5) 0.466 60 8.0 (2.5) 0.446
Males 37 7.7 (2.5) 35 7.0 (3.2) 36 7.6 (2.7)
3. Personal control: How much control do you feel you have over your illness?
Females 61 5.9 (1.9) 0.354 61 6.4 (2.0) 0.177 62 6.8 (2.0) 0.351
Males 37 6.3 (2.0) 35 7.0 (1.9) 36 7.2 (2.5)
4. Treatment control: How much do you think your treatment can help your illness?
Females 61 7.0 (2.2) 0.616 61 7.8 (2.3) 0.098 62 8.0 (2.0) 0.031
Males 37 7.2 (2.6) 35 8.5 (1.5) 36 8.7 (1.4)
5. Identity: How much do you experience symptoms from your illness?
Females 61 7.6 (2.0) 0.964 60 5.4 (2.6) 0.503 62 5.9 (2.4) 0.026
Males 37 7.5 (1.5) 35 5.0 (2.7) 36 4.8 (2.5)
6. Concern: How concerned are you about your illness?
Females 61 7.2 (2.5) 0.490 61 5.4 (2.7) 0.519 62 6.1 (2.8) 0.039
Males 36 7.6 (2.3) 35 5.8 (2.7) 36 4.9 (2.7)
7. Illness comprehension: How well do you feel you understand your illness?
Females 61 6.7 (2.4) 0.038 60 7.3 (2.1) 0.118 62 7.6 (2.1) 0.790
Males 37 7.7 (2.1) 35 8.0 (2.2) 36 7.8 (2.3)
8. Emotions: How much does your illness affect you emotionally?
Females 61 7.0 (2.8) 0.305 60 5.7 (2.8) 0.492 62 6.2 (2.7) 0.005
Males 37 6.5 (2.6) 35 5.3 (2.5) 36 4.6 (2.6)
Total score
Females 60 50.9 (8.1) 0.154 58 40.6 (9.8) 0.287 60 41.8 (9.4) 0.007
Males 36 48.4 (8.3) 35 38.2 (11.4) 36 35.6 (12.0)
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In this respect, our results are in line with several previous 
studies demonstrating that females frequently report 
worse asthma related QoL [14, 15, 27, 31, 32]. However, 
it should be underlined that asthma was more severe in 
females from baseline, as measured by the FEV1, which 
was significantly lower in females.
One peculiar aspect of the PROXIMA study was 
precisely the evaluation, as secondary objectives, of the 
perceived burden of disease by means of patient reported 
outcomes (PROs) [17]. Indeed, the patient’s point of view 
is increasingly becoming an important part of treatment 
evaluation. However, only a minority of asthma trials 
have included PROs among their assessment measures 
and even less in a real-life setting [33]. In this by-gender 
analysis of the PROXIMA real-life results, PROs are 
exactly what makes the difference between males and 
females with severe asthma. Patients of both genders 
achieved similar levels of asthma control and experienced 
overall improvement in QoL over 1  year of omalizumab 
add-on therapy, but females reported a worse overall 
perception of the disease and complained worse symptom 
experience and greater emotional impact. Moreover, 
they expressed more concern about the disease and felt 
a greater impairment of their QoL, impacting their usual 
daily activities and producing more discomfort and 
anxiety/depression, as explored by EQ-5D-3 L. Female 
sex hormones are hypothesized to affect these outcomes 
[10, 34], however other factors have been claimed, such as 
different behaviors of asthmatic males and females [34]—
females have shown a lower threshold for healthcare 
contact requirement [35]—, different adherence to 
medications—females seem to need more encouragement 
and education that males regarding the correct use of 
inhalers [36]—, and different attitudes of caregivers 
toward males and females—with for example females 
undergoing less spirometry testing [37]. Concerning 
medications, it may be interesting to report that our 
female population showed a trend toward a greater use of 
OCS and a lower use of pure inhaled medications.
This study has the important limitation of being a 
post hoc analysis of a study that had not originally been 
designed with the aim of detecting gender differences. 
It also carries the limitation of the original PROXIMA 
Fig. 2 Mean EuroQoL score by gender at baseline and at 6 and 12 months of follow-up. Mean and SD of EuroQol score are showed. *T-test 
(EuroQol score males vs females) p < 0.05
Table 6 Repeated measures multivariate regression: effect 
of gender on EuroQol score
Estimate Standard Error p-value
Intercept 0.820 0.071 < 0.0001
Gender (females vs males) − 0.055 0.024 0.028
Visit (6-month follow up vs 
baseline)
0.093 0.015 < .0.0001
Visit (12-month follow up vs 
baseline)
0.099 0.015 < .0.0001
Age (years) 0.000 0.001 0.826
Comorbidities (no vs yes) 0.037 0.025 0.147
Smoke (current/former vs no 
smoker)
− 0.009 0.028 0.752
Asthma duration (years) 0.000 0.001 0.712
ICS (no vs yes) − 0.026 0.029 0.382
ICS + LABA (no vs yes) − 0.032 0.041 0.439
OCS (no vs yes) 0.039 0.036 0.278
Omalizumab total dose (mg) 0.000 0.003 0.510
Exacerbations in the 12 months 
before enrollment (0 vs ≥ 1)
0.052 0.063 0.409
Page 9 of 10Colombo et al. Allergy Asthma Clin Immunol           (2019) 15:65 
study of a higher numerical imbalance between sexes 
than reported in the literature. Furthermore, the use of 
questionnaire in the PROXIMA study may have implied 
a potential risk of selection bias owing to exclusion 
of patients who were considered unable to complete 
them. Another limitation is that, despite the choice of 
standardized questionnaires, several PROXIMA findings 
were based on self-report and thus subject to recall bias. 
On the other hand, our post hoc gender analysis has 
the merit of providing real-world information about the 
differences in PROs from males and females with severe 
asthma. The absence of spirometry data at the 6 and 
12 months, that would have allowed to correlate objective 
measures of respiratory function of our SAA patients to 
their ACQ and QoL scores, is another limitation due to 
the post hoc nature of our study.
Conclusions
In this real-world setting, females confirmed to have a 
worse perception of the disease, feel the disease as more 
symptomatic and suffer a greater impact on their daily 
activities and QoL, even though having similar baseline 
severity and obtaining similar level of disease control. 
As emerged from other MetaGeM post hoc analyses, the 
impact of conditions and therapies on males and females 
may be significantly different. We believe that better 
understanding gender differences in diseases in general, 
and in asthma in particular, is of major importance in 
order to provide personalized education and management 
across the life course.
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